Abstract
Plasma or serum protein binding determinations of extensively bound drugs are subject to serious error if the analytical methods employed do not discriminate between such drugs and their degradation products, metabolites, and impurities. Experimental evidence is presented to demonstrate the magnitude of this problem with respect to warfarin.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
